Teladoc Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Teladoc Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.41B | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $2.03B | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $1.09B | Mar 1, 2023 |
| FY2018 | Dec 31, 2018 | $122.74M | Feb 27, 2019 |
| FY2018 | Sep 30, 2018 | $110.96M | Feb 27, 2019 |
| FY2018 | Jun 30, 2018 | $94.56M | Feb 27, 2019 |
| FY2018 | Mar 31, 2018 | $89.64M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $77.14M | Feb 27, 2019 |
| FY2018 | Sep 30, 2017 | $68.65M | Feb 27, 2019 |
| FY2018 | Jun 30, 2017 | $44.59M | Feb 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.57B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.60B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.41B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.03B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.09B | Mar 1, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $82.71M | Feb 27, 2019 |
| FY2018 | Sep 30, 2018 | $76.80M | Feb 27, 2019 |
| FY2018 | Jun 30, 2018 | $66.88M | Feb 27, 2019 |
| FY2018 | Mar 31, 2018 | $62.79M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $54.42M | Feb 27, 2019 |
| FY2018 | Sep 30, 2017 | $51.91M | Feb 27, 2019 |
| FY2018 | Jun 30, 2017 | $34.57M | Feb 27, 2019 |
| FY2018 | Mar 31, 2017 | $30.76M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $27.38M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $25.27M | Feb 27, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($200.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.00B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($220.37M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($13.66B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($428.79M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($485.14M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($19.04M) | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | ($20.35M) | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | ($29.32M) | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | ($30.15M) | Feb 26, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($262.96M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.02B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($248.55M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($13.65B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($265.63M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($506.42M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($15.59M) | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | ($19.94M) | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | ($22.02M) | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | ($22.89M) | Feb 26, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $277.92M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $307.27M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $348.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $333.63M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $311.88M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $164.94M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $16.25M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $15.75M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $16.67M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $15.99M | Feb 26, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $294.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $293.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $350.02M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $189.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $193.99M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($53.51M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $29.87M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($4.86M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($34.44M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($51.88M) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $11.46M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $16.48M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.53M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $4.02M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $3.51M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $4.01M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $2.63M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.11M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.52B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.39B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.35B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $17.73B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $17.76B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.60B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.53B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $824.39M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $303.67M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.03B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.07B | Feb 27, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.33B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $2.31B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $16.05B | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $15.88B | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $1.01B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $1.01B | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $558.90M | Mar 1, 2021 |
| FY2018 | Dec 31, 2016 | $230.87M | Feb 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $283.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $283.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.07B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.07B | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | $14.50B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $14.58B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $746.08M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $737.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $498.52M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $188.18M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.43B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($16.23B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.23B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($15.01B) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | ($1.42B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($992.66M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($507.53M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($408.66M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($311.58M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($204.73M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $781.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.30B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.12B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $918.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $893.48M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $733.32M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $514.35M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $423.99M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $42.82M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $50.02M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $44.42M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $26.48M | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $25.87M | Mar 3, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (84) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (5) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (84) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (5) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 178.32M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 173.41M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 166.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 162.84M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 160.47M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 150.28M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 72.76M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 70.52M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 61.53M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 46.20M | Feb 27, 2018 |